Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
2 passages
©2013 UpToDate ® Print Email ACC/AHA/ESC guidelines: recommendations for pharmacologic cardioversion of AF ≤7 days duration* Antiarrhythmic drug* Route of administration Class of recommendation Drugs proven effective Dofetilide Oral I Flecainide Oral or intravenous I Ibutilide Intravenous I Propafenone Oral or intravenous I Amiodarone Oral or intravenous IIa Drugs that are less effective or incompletely studied Disopyramide Intravenous IIb Procainamide Intravenous IIb Quinidine Oral IIb Drugs that should not be given Digoxin Oral or intravenous III Sotalol Oral or intravenous III * The doses of medications used in these studies may not be the same as those recommended by the manufacturers. Data from: Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.
©2013 UpToDate ® Print Email ACC/AHA/ESC guidelines: recommendations for pharmacologic cardioversion of AF ≤7 days duration* Antiarrhythmic drug* Route of administration Class of recommendation Drugs proven effective Dofetilide Oral I Flecainide Oral or intravenous I Ibutilide Intravenous I Propafenone Oral or intravenous I Amiodarone Oral or intravenous IIa Drugs that are less effective or incompletely studied Disopyramide Intravenous IIb Procainamide Intravenous IIb Quinidine Oral IIb Drugs that should not be given Digoxin Oral or intravenous III Sotalol Oral or intravenous III * The doses of medications used in these studies may not be the same as those recommended by the manufacturers. Data from: Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149. ACC/AHA/ESC Guideline Summary: Pharmacologic cardioversion of AF >7 days duration* Antiarrhythmic drug* Route of administration Class of recommendation Drugs proven effective Dofetilide Oral I Amiodarone Oral or intravenous IIa Ibutilide Intravenous IIa Drugs that are less effective or incompletely studied Disopyramide Intravenous IIb Flecainide Oral IIb Procainamide Intravenous IIb Propafenone Oral or intravenous IIb Quinidine Oral IIb Drugs that should not be given Digoxin Oral or intravenous III Sotalol Oral or intravenous III * The doses of medications used in these studies may not be the same as those recommended by the manufacturers. Data from Fuster, V, Ryden, LE, Cannom, DS, etal. ACC/AHA/ESC guidelines for the management of patients with atrialfibrillation. A report of the American College of Cardiology/AmericanHeart Association Task Force on Practice Guidelines and the EuropeanSociety of Cardiology Committee for Practice Guidelines (Writingcommittee to revise the 2001 guidelines for the management of patientswith atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.